Dareen D. Siri
Distinguished in Common Variable Immune Deficiency

Dr. Dareen D. Siri

Allergy and Immunology
2010 Jacobssen Dr, 
Normal, IL 
Accepting New Patients
Distinguished in Common Variable Immune Deficiency
2010 Jacobssen Dr, 
Normal, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dareen Siri is an Allergy and Immunologist in Normal, Illinois. Dr. Siri is rated as a Distinguished provider by MediFind in the treatment of Common Variable Immune Deficiency. Her top areas of expertise are Primary Immunodeficiency (PID), Common Variable Immune Deficiency, Sinusitis, and Allergic Rhinitis. Dr. Siri is currently accepting new patients.

Her clinical research consists of co-authoring 9 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Un Of California, Irvine, College Of Medicine
Specialties
Allergy and Immunology
Licenses
Internal Medicine in IL
Hospital Affiliations
Memorial Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Celtic
  • HMO
  • INSURANCE PLAN
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

MIDWEST ALLERGY SINUS ASTHMA SC
2010 Jacobssen Dr, Normal, IL 61761

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Enrollment Status: Completed
Publish Date: December 17, 2024
Intervention Type: Drug, Biological
Study Drug: GSK3511294
Study Phase: Phase 3
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: CDX-0159, Normal Saline
Study Phase: Phase 1
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
Safety Study of Viaskin Peanut to Treat Peanut Allergy
Safety Study of Viaskin Peanut to Treat Peanut Allergy
Enrollment Status: Completed
Publish Date: February 03, 2021
Intervention Type: Biological
Study Phase: Phase 3
A Phase 2 Multicenter Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Adult Subjects With Pruritus Associated With Atopic Dermatitis
A Phase 2 Multicenter Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Adult Subjects With Pruritus Associated With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: December 13, 2017
Intervention Type: Drug
Study Phase: Phase 2
A Double-Blind, Randomized, Crossover Allergy Study of an Experimental Formula Followed by a 16 Week Double Blind Feeding Period to Assess Growth, Safety and Development of Tolerance to Cow's Milk Protein
A Double-Blind, Randomized, Crossover Allergy Study of an Experimental Formula Followed by a 16 Week Double Blind Feeding Period to Assess Growth, Safety and Development of Tolerance to Cow's Milk Protein
Enrollment Status: Completed
Publish Date: June 08, 2017
Intervention Type: Other
Study Phase: Not Applicable
View 9 Less Clinical Trials

9 Total Publications

Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study.
Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study.
Journal: Journal of the American Academy of Dermatology
Published: December 13, 2024
Similar Doctors
Experienced in Common Variable Immune Deficiency
Dr. Bethany T. Gibson
Allergy and Immunology
Experienced in Common Variable Immune Deficiency
Dr. Bethany T. Gibson
Allergy and Immunology
101 W Mckinley Ave, Enta Allergy, Head & Neck Institute, 
Decatur, IL 
 (45.0 miles away)
217-876-3682
Languages Spoken:
English
See accepted insurances

Bethany Gibson is an Allergy and Immunologist in Decatur, Illinois. Dr. Gibson is rated as an Advanced provider by MediFind in the treatment of Common Variable Immune Deficiency. Her top areas of expertise are Sinusitis, Nonallergic Rhinopathy, Allergic Rhinitis, and Grass Allergy.

Experienced in Common Variable Immune Deficiency
Dr. Julie C. Klemens
Allergy and Immunology
Experienced in Common Variable Immune Deficiency
Dr. Julie C. Klemens
Allergy and Immunology

Peoria Ear Nose And Throat Group Sc

7301 N Knoxville Ave, 
Peoria, IL 
 (38.9 miles away)
309-589-5900
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Julie Klemens is an Allergy and Immunologist in Peoria, Illinois. Dr. Klemens is rated as a Distinguished provider by MediFind in the treatment of Common Variable Immune Deficiency. Her top areas of expertise are Grass Allergy, Nonallergic Rhinopathy, Ozena, and Sinusitis. Dr. Klemens is currently accepting new patients.

Experienced in Common Variable Immune Deficiency
Dr. Stephen J. Smart
Allergy and Immunology
Experienced in Common Variable Immune Deficiency
Dr. Stephen J. Smart
Allergy and Immunology

Springfield Clinic, Llp

6615 N Big Hollow Rd, 
Peoria, IL 
 (41.2 miles away)
309-691-5200
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Stephen Smart is an Allergy and Immunologist in Peoria, Illinois. Dr. Smart is rated as an Advanced provider by MediFind in the treatment of Common Variable Immune Deficiency. His top areas of expertise are Vibratory Urticaria, Chronic Spontaneous Urticaria (CSU), Hives, and Allergic Rhinitis. Dr. Smart is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Siri's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile